Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prospective cohort study of biologics and small-molecule targeted drugs for delaying progression of subclinical psoriatic arthritis
ChiCTR2600132588Phase 4Recruiting
- Sponsor
- Shandong First Medical University Affiliated Dermatology Hospital
- Start
- Sep 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of methotrexate, apremilast, deucravacitinib and upadacitinib in psoriatic arthritis (PsA) (3 arms), sponsored by Shandong First Medical University Affiliated Dermatology Hospital. Primary endpoints: Cumulative prevalence of psoriatic arthritis, Progression on joint ultrasound imaging and 1 more. Started Sep 2025; status: recruiting.
02
Drugs
methotrexateapremilastdeucravacitinibupadacitinib
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on ChiCTR2600132588.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600132588.